临床流行病学核心概念:随机对照试验中偏倚来源的识别与报告
随机对照试验虽被视为评估临床干预效果最稳健的设计,但即使实施良好的试验也存在常见偏倚来源。本文以修订版Cochrane偏倚风险工具(RoB 2)的五域框架为基础,提出建议帮助研究者减轻这些偏倚并确保报告透明,使研究使用者知晓偏倚来源。
要点
- RoB 2区分随机化过程、偏离预期干预、结局数据缺失、结局测量和结果报告五个偏倚域。
- 即使实施良好的试验也存在常见偏倚来源,威胁对观察效应的解读。
- 建议以RoB 2为框架减轻偏倚并确保报告透明。
核心结论
- 随机对照试验存在五类常见偏倚来源,需以RoB 2为框架加以识别、减轻并透明报告。
研究设计与样本
- 本文为临床流行病学概念解读文章,以修订版Cochrane偏倚风险工具(RoB 2)为框架提出建议。
主要发现
- RoB 2区分五个偏倚域:随机化过程、偏离预期干预、结局数据缺失、结局测量和结果报告。
临床怎么用
- 研究者可依据RoB 2五域框架减轻偏倚并透明报告,使研究使用者知晓偏倚来源。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Randomized controlled trials are widely considered the most robust design for evaluating the effects of clinical interventions. While generalisability is often limited, randomization aims to ensure that effects observed are genuine. However, there are common sources of bias, even in well-conducted trials, that pose a threat to this interpretation. The revised Cochrane risk-of-bias tool for trials (RoB 2) distinguishes five domains of bias that can affect the results of trials stemming from (1) the randomization process, (2) deviations from intended interventions, (3) missing outcome data, (4) outcome measurement, and (5) reporting of findings. We use RoB 2 as a framework for recommendations to help researchers mitigate these sources of bias and ensure transparency in reporting so that users of research are aware of them.
引用
- Kotz D, West R. Key concepts in clinical epidemiology: addressing and reporting sources of bias in randomized controlled trials. J Clin Epidemiol. 2021. PMID: 34571193. doi:10.1016/j.jclinepi.2021.09.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。